Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in. | February 28, 2023
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace
Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2022 Results - Earnings Call Transcript seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.